Aquestive Therapeutics, Inc. reported $54M of revenue over the trailing twelve months, +23% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $54M (to Q2 2026). Net income: −$78M, trailing twelve months to Q2 2026. Free cash flow: −$46M, trailing twelve months to Q2 2026. Operating margin: −100%, trailing twelve months to Q2 2026.

AQSTAquestive Therapeutics, Inc.

Healthcare

$4.77-20% 1Y

$4.77

$2.9552 weeks$7.49

AQST as reported

Aquestive Therapeutics, Inc. reported $54M of revenue over the trailing twelve months, +23% on the year before. 10 reported series are charted on this page, each one as filed.

$54M

Revenue, trailing twelve months · to Q2 2026 · +23% against the twelve months before

Net income: −$78M
Net income · +20% year on year · trailing twelve months to Q2 2026
Free cash flow: −$46M
Free cash flow · −8.1% year on year · trailing twelve months to Q2 2026
Operating margin: −100%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for AQST, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$54M	+23%	Q2 2026
Net income	−$78M	+20%	Q2 2026
EPS	−$0.66	−5.7%	Q2 2026
Gross margin	67%	n/a	Q2 2026
Operating margin	−100%	n/a	Q2 2026
Net margin	−147%	n/a	Q2 2026
ROE	567%	n/a	Q2 2026
ROA	−51%	n/a	Q2 2026
ROIC	47%	n/a	Q2 2026
Free cash flow	−$46M	−8.1%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.